Atherectomy is one of the important peripheral arterial disease treatment, in which, atherosclerosis from large blood vessels are removed by using minimally invasive surgical approach. In addition, this technique is used for the treatment of coronary arterial diseases. Thromboctomy, also known as pulmonary thromboctomy, is an emergency medical treatment, by which thrombus (blood clot) is removed from arteries and veins. Thromboctomy can be performed by two technologies, by using surgery or by percutaneous techniques. However, surgical thromboctomy technique is used rarely, due to less efficient results and high cost.
Request Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4584
Atherectomy technique is a popular substitute for stents and angioplasty treatment. In case of latter, the deposited plaque is pushed inside blood vessel, however, in former, the plaque is removed by using surgical or mechanical technique. This technique has certain advantages over angioplasty and stents, such as, increased wound healing rate, reduction in claudication, reduction in threat of cardiac and other medical complications, less invasive nature, faster patient recovery, high repeatability, ease-of-performance and many others. The device is inserted in the body by making small incision to certain locations of body, such as, common femoral artery, political artery, bronchial artery and others.
The market of Atherectomy devices is segmented on the basis of type and mechanism of device functions, such as, orbital, laser, rotational and directional devices. However, preference of device is based on factors such as, nature and size of plaque, anatomical place to be treated, and surgeon’s expertise. The market for thromboctomy is also segmented on the basis of device type, such as, rotational, ultrasound enhanced and rheolytic thromboctomy devices. In addition, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, the North American region is the most prominent market, owing to increasing technological intervention in cardiac disease management. However, Asia-Pacific and some countries in RoW region are expected to show very lucrative growth in the upcoming period, owing to enhanced awareness and growth in prevalence of cardiac patients and technologies.
The market for atherectomy and thromboctomy devices is expected to grow in the upcoming future at a lucrative rate, due to various market drivers, such as rapid increase in the cardiac diseases, changed life-style, increasing preference towards less invasive cardiac disease management practices, less risks involved in the procedure, decreased use of surgical practices for cardiac diseases treatment and technological growth in the development of advanced devices. Rising prevalence of cardiac disorders is one of the most important market driver. According to the U.S. Center for Disease Control and Prevention (CDC), around 0.6 million of Americans die every year due to cardiac diseases, and around 720,000 Americans have a heart attack every year.
Further, changed life-style is another contributor for the market growth. Due to consumption of junk food, addiction and lack of exercise, the prevalence of cardiac diseases have been increased and it contributes the market growth of Atherectomy and thromboctomy devices. On the contrary, major restraints that impose hurdles in the market growth include high cost, limited awareness in certain region of the world. Key opportunities include development of cost-effective therapy and strong focus on APAC region (since, India and China possess the largest number of cardiac patients).
Some of the major players operating in the market include Bayer AG, Cardiovascular Systems, Inc., St. Jude Medical Inc., Boston Scientific Corporation, C.R. Bard, inc., Teleflex Medical Inc., and Covidien, Inc. among others.
